| 臺大學術典藏 |
2022-09-15T01:09:00Z |
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|
Drilon A.; Siena S.; Dziadziuszko R.; Barlesi F.; Krebs M.G.; Shaw A.T.; de Braud F.; Rolfo C.; Ahn M.-J.; Wolf J.; Seto T.; Cho B.C.; Patel M.R.; Chiu C.-H.; John T.; Goto K.; Karapetis C.S.; Arkenau H.-T.; Kim S.-W.; Ohe Y.; Li Y.-C.; Chae Y.K.; Chung C.H.; Otterson G.A.; Murakami H.; Chia-Chi Lin; Tan D.S.W.; Prenen H.; Riehl T.; Chow-Maneval E.; Simmons B.; Cui N.; Johnson A.; Eng S.; Wilson T.R.; Doebele R.C. |
| 臺大學術典藏 |
2022-09-15T01:08:52Z |
Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)
|
Bang Y.-J.; Golan T.; Dahan L.; Fu S.; Moreno V.; Park K.; Geva R.; De Braud F.; Wainberg Z.A.; Reck M.; Goff L.; Laing N.; Mi G.; Oliveira J.M.; Wasserstrom H.; Chia-Chi Lin |
| 臺大學術典藏 |
2020-05-25T07:35:07Z |
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer
|
Saraf S; Thanigaimani P; Cheng J.D; Keam B.; Mehnert J.M; Varga A; Brose M.S; Aggarwal R.R; Chia-Chi Lin; Prawira A; De Braud F; Tamura K; Doi T; Piha-Paul S.A; Gilbert J |
| 臺大學術典藏 |
2020-05-25T07:35:06Z |
Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2
|
Barlesi F; Drilon A; De Braud F; Cho B.C; Ahn M.J; Siena S; Krebs M.G; Chia-Chi Lin; John T; Tan D.S.W; Seto T; Dziadziuszko R; Arkenau H.-T; Rolfo C; Wolf J; Ye C; Riehl T; Eng S; Doebele R.C. |
| 臺大學術典藏 |
2020-05-25T07:35:02Z |
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1�V2 trials
|
Rolfo C; de Braud F; Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs M.G; Shaw A.T; Doebele R.C.;Wilson T.R;Eng S;Johnson A;Cui N;Simmons B;Chow-Maneval E;Riehl T;Prenen H;Tan D.S.W;Chia-Chi Lin;Murakami H;Otterson G.A;Chung C.H;Chae Y.K;Li Y.-C;Ohe Y;Kim S.-W;Arkenau H.-T;Karapetis C.S;Goto K;John T;Chiu C.-H;Patel M.R;Cho B.C;Seto T;Wolf J;Ahn M.-J;Rolfo C;de Braud F;Shaw A.T;Krebs M.G;Barlesi F;Dziadziuszko R;Siena S;Drilon A; Ahn M.-J; Wolf J; Seto T; Cho B.C; Patel M.R; Chiu C.-H; John T; Goto K; Karapetis C.S; Arkenau H.-T; Kim S.-W; Ohe Y; Li Y.-C; Chae Y.K; Chung C.H; Otterson G.A; Murakami H; Chia-Chi Lin; Tan D.S.W; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson T.R; Doebele R.C. |
| 臺大學術典藏 |
2020-05-25T07:35:02Z |
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1�V2 trials
|
Rolfo C; de Braud F; Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs M.G; Shaw A.T; Doebele R.C.;Wilson T.R;Eng S;Johnson A;Cui N;Simmons B;Chow-Maneval E;Riehl T;Prenen H;Tan D.S.W;Chia-Chi Lin;Murakami H;Otterson G.A;Chung C.H;Chae Y.K;Li Y.-C;Ohe Y;Kim S.-W;Arkenau H.-T;Karapetis C.S;Goto K;John T;Chiu C.-H;Patel M.R;Cho B.C;Seto T;Wolf J;Ahn M.-J;Rolfo C;de Braud F;Shaw A.T;Krebs M.G;Barlesi F;Dziadziuszko R;Siena S;Drilon A; Ahn M.-J; Wolf J; Seto T; Cho B.C; Patel M.R; Chiu C.-H; John T; Goto K; Karapetis C.S; Arkenau H.-T; Kim S.-W; Ohe Y; Li Y.-C; Chae Y.K; Chung C.H; Otterson G.A; Murakami H; Chia-Chi Lin; Tan D.S.W; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson T.R; Doebele R.C. |
| 臺大學術典藏 |
2017 |
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
|
Kim S.-B.;Maslyar D.J.;Dent R.;Im S.-A.;Espi? M.;Blau S.;Tan A.R.;Isakoff S.J.;Oliveira M.;Saura C.;Wongchenko M.J.;Kapp A.V.;Chan W.Y.;Singel S.M.;Baselga J.;Kim S.-B.;Lee K.S.;Im S.-A.;Espi? M.;Wang H.-C.;Blau S.;Dent R.;Tan A.;Sohn J.H.;De Laurentiis M.;Estevez L.G.;Chiun-Sheng Huang;Romieu G.;Velez M.;Villanueva R.;Conte P.F.;Dakhil S.;Debled M.;Martin A.G.;Hurvitz S.;Kim J.H.;Levy C.;Oliveira M.;Rovira P.S.;Seo J.H.;Valero V.;Vidal G.;Wong A.;Allison M.A.K.;Figlin R.;Chan D.;Chen S.-C.;Chen Y.-H.;Cobleigh M.;De Braud F.;Dirix L.;Hansen V.;Bessard A.H.;Iannotti N.;Isakoff S.;Lawler W.;Monta?O A.;Salkini M.;Seigel L.;On Behalf Of The, Lotus Investigators, Lotus Investigators; Estevez L.G.; De Laurentiis M.; Sohn J.H.; Wang H.-C.; Blau S.; Dent R.; Tan A.; Espi? M.; Im S.-A.; Lee K.S.; Kim S.-B.; Baselga J.; Kim S.-B.; Maslyar D.J.; Dent R.; Im S.-A.; Espi? M.; Blau S.; Tan A.R.; Isakoff S.J.; Oliveira M.; Saura C.; Wongchenko M.J.; Kapp A.V.; Chan W.Y.; Singel S.M.; Allison M.A.K.; Vidal G.; Wong A.; Valero V.; Seo J.H.; CHIUN-SHENG HUANG; Romieu G.; Velez M.; Villanueva R.; Conte P.F.; Dakhil S.; Debled M.; Martin A.G.; Hurvitz S.; Kim J.H.; Levy C.; Oliveira M.; Rovira P.S.; on behalf of the, LOTUS investigators, LOTUS investigators; Seigel L.; Salkini M.; Monta?o A.; Figlin R.; Chan D.; Chen S.-C.; Chen Y.-H.; Cobleigh M.; De Braud F.; Dirix L.; Hansen V.; Bessard A.H.; Iannotti N.; Isakoff S.; Lawler W. |
| 臺大學術典藏 |
2017 |
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
|
Kim S.-B.;Maslyar D.J.;Dent R.;Im S.-A.;Espi? M.;Blau S.;Tan A.R.;Isakoff S.J.;Oliveira M.;Saura C.;Wongchenko M.J.;Kapp A.V.;Chan W.Y.;Singel S.M.;Baselga J.;Kim S.-B.;Lee K.S.;Im S.-A.;Espi? M.;Wang H.-C.;Blau S.;Dent R.;Tan A.;Sohn J.H.;De Laurentiis M.;Estevez L.G.;Chiun-Sheng Huang;Romieu G.;Velez M.;Villanueva R.;Conte P.F.;Dakhil S.;Debled M.;Martin A.G.;Hurvitz S.;Kim J.H.;Levy C.;Oliveira M.;Rovira P.S.;Seo J.H.;Valero V.;Vidal G.;Wong A.;Allison M.A.K.;Figlin R.;Chan D.;Chen S.-C.;Chen Y.-H.;Cobleigh M.;De Braud F.;Dirix L.;Hansen V.;Bessard A.H.;Iannotti N.;Isakoff S.;Lawler W.;Monta?O A.;Salkini M.;Seigel L.;On Behalf Of The, Lotus Investigators, Lotus Investigators; Estevez L.G.; De Laurentiis M.; Sohn J.H.; Wang H.-C.; Blau S.; Dent R.; Tan A.; Espi? M.; Im S.-A.; Lee K.S.; Kim S.-B.; Baselga J.; Kim S.-B.; Maslyar D.J.; Dent R.; Im S.-A.; Espi? M.; Blau S.; Tan A.R.; Isakoff S.J.; Oliveira M.; Saura C.; Wongchenko M.J.; Kapp A.V.; Chan W.Y.; Singel S.M.; Allison M.A.K.; Vidal G.; Wong A.; Valero V.; Seo J.H.; CHIUN-SHENG HUANG; Romieu G.; Velez M.; Villanueva R.; Conte P.F.; Dakhil S.; Debled M.; Martin A.G.; Hurvitz S.; Kim J.H.; Levy C.; Oliveira M.; Rovira P.S.; on behalf of the, LOTUS investigators, LOTUS investigators; Seigel L.; Salkini M.; Monta?o A.; Figlin R.; Chan D.; Chen S.-C.; Chen Y.-H.; Cobleigh M.; De Braud F.; Dirix L.; Hansen V.; Bessard A.H.; Iannotti N.; Isakoff S.; Lawler W. |
